Capsugel Vcaps® Enteric, a ready-to-use solution. Save cost and time during pharmaceutical development or compounding.
The development of oral pharmaceutical dosage forms is seeing some of the fastest concept to market times in pharmaceutical history when considering the number of fast-track and breakthrough product designations. Today's pharmaceutical development group, from scientist to executive, faces an ever important challenge not only to develop world class therapies but also to deliver them in a fast, efficient timeline. Technologies which enable pharmaceutical groups to accomplish that mission are the go-to strategies of today and tomorrow.
Acid sensitive active ingredients face their own set of challenges in the R&D, clinical and manufacturing stages of development. Most often formulating for these actives involve challenging, labor intensive operations which can impact both timelines and cost dramatically as the industry relies on the coating of multiparticulates and/or solid oral dosage units to achieve protection. Certainly these are valuable avenues but often result in chemical compatibility issues, additional processing steps, and reduced product yields. The industry has searched for methods of providing quicker, simpler access to acid protection to alleviate these various issues to provide pharmaceutical products for patients in need.
Today, the largest portfolio of hard capsule options exist to achieve immediate, delayed, controlled release and now enteric protection. In this webinar, Lonza experts will discuss an important recent development, the Capsugel Vcaps® Enteric capsule, a non-gelatin capsule that offers innate enteric protection without the requirement of a functional coating or the accompanying processing steps. These capsules offer opportunities to accelerate speed-to-market and act as thought starters for new product development. Register now to take advantage of both the webinar and access to technical professionals ready to discuss your questions and strategies today.
Presented by
Matt Richardson, Ph.D.,
Manager – Pharmaceutical Business Development
Dr. Matt Richardson is currently the Manager of Biopharmaceutical Business Development for Capsule Delivery Solutions, part of Lonza Pharma and Biotech and is based out of the Greenwood, South Carolina site.
Matt has been with Capsugel for 12 years and has worked with many pharmaceutical and nutraceutical customers to understand the formulation aspects of their products with two-piece hard capsules and has been an invited speaker at numerous seminars and webinars on topics of hard capsules, such as: crosslinking, capsules for use in delayed release, as well as DPI-based inhalation.
He is a graduate of Wofford College, holds a doctorate in Synthetic Organic Chemistry from Wake Forest University and a post-doctoral appointment at Virginia Tech.
Christian Klein, M.Sc.,
Manager – Pharmaceutical Business Development
Christian Klein is currently the Manager of Biopharmaceutical Business Development for Capsule Delivery Solutions, part of Lonza Pharma and Biotech and is based out of the Colmar, France site.
Christian has been with Capsugel for 5 years and has worked with many pharmaceutical customers to understand the formulation aspects of their products related to crosslinking issues, targeted release, and other aspects of polymer science. He holds a Master degree in Analytical Chemistry from Louis Pasteur University (Strasbourg, France).